Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis

Immunological Reviews

Volumn 180, Issue , 2001, Pages 162-167

  Campbell, William ^a   Okada, Noriko ^b   Okada, Hidechika ^b  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; ARGININE CARBOXYPEPTIDASE; AUTACOID; BACTERIUM LIPOPOLYSACCHARIDE; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE R; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; LYSINE; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; COMPLEMENT INHIBITION; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME INHIBITION; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; HYDROLYSIS; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEPTIC SHOCK; THROMBOSIS;

ANAPHYLATOXINS; ANIMALS; BACTERIAL INFECTIONS; CARBOXYPEPTIDASE U; COMPLEMENT C3A; COMPLEMENT C5A; DRUG DESIGN; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PRECURSORS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; RABBITS; RATS; SHOCK, SEPTIC; THROMBOLYTIC THERAPY; THROMBOMODULIN; TRANSFECTION;

EID: 0034996440     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1800114.x     Document Type: Review

References (39)

1. 1. Plummer TH Jr, Hurwitz MY. Human plasma carboxypeptidase N. Isolation and characterization. J Biol Chem 1978;11:3907-3912.
2. 2. Skidgel RA. Basic carboxypeptidases: regulators of peptide hormone activity. Trends Pharmacol Sci 1988;9:299-304.
3. 3. Tan F, Jackman H, Skidgel RA, Zsigmond EK, Erdos EG. Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins. Anesthesiology 1989;70:267-275.
4. 4. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989;161:933-939.
5. 5. Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989;27:277-285.
6. 6. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991;266:21833-21838.
7. 7. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994;269:15937-15944.
8. 8. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.
9. 9. Sheikh IA, Kaplan AP. Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem Pharmacol 1986;35:1957-1963.
10. 10. Skidgel RA, Kawahara MS, Hugli TE. Functional significance of the subunits of carboxypeptidase N (kininase I). Adv Exp Med Biol 1986;198(Pt A):375-380.
11. 11. Kato K, Shinagawa N, Hayakawa N, Takayama H, Campbell W, Okada H. Changes in arginine carboxypeptidase in stressed rats. Pathophysiology 1994;1:131-136.
12. 12. Pangburn MK, Shreiber RD, Muller-Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway. J Exp Med 1981;154:856-867.
13. 13. Nicholson-Weller A. Decay accelerating factor (DC55). Curr Top Microbiol Immunol 1992;178:7-30.
14. 14. Ballard L, Seya T, Techman L, Lublin DM, Atkinson JP. A polymorphism of the complement regulatory protein MCP (membrane cofactor protein or gp45-70). J Immunol 1987;138:3850-3855.
15. 15. Kinoshita T, Takata Y, Kozono H, Takeda J, Hong K, Inoue K. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol 1988;141:3895-3901.
16. 16. Rother K, Till GO. The complement system. Berlin, Heidelberg, New York: Springer-Verlag; 1988.
17. 17. Shinohara T, et al. Pro-carboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol 1994;103:400-404.
18. 18. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000;12:2511-2518.
19. 19. Sato T, et al. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000;165:1053-1058.
20. 20. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-2100.
21. 21. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-16608.
22. 22. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:2792-2798.
23. 23. Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999;38:6547-6558.
24. 24. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996;88:3815-3823.
25. 25. Broze GJ Jr. Thrombin-dependent inhibition of fibrinolysis. Curr Opin Hematol 1996;3:390-394.
26. 26. Mosnier LO, dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998;80:829-835.
27. 27. Nagashima M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000;98: 333-342.
28. 28. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997;78:386-391.
29. 29. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998;273:27176-27181.
30. 30. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996;93:1328-1330.
31. 31. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-4746.
32. 32. Jackson DE, Tetaz TJ, Salem HH, Mitchel CA. Purification and characterization of two forms of soluble thrombomodulin from human urine. Eur J Biochem 1994;221:1079-1087.
33. 33. Hosaka Y, Takahashi Y, Ishii H, Thrombomodulin in human plasma contributes co inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma carboxypeptidase B. Thromb Haemost 1998;79:371-377.
34. 34. Tanaka A, Ishii H. Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991;37:269-272.
35. 35. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990;76:2024-2029.
36. 36. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997;272:14477-14482.
37. 37. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999;94:2735-2743.
38. 38. Gurewich V, Liu JN, Pannell R. The intrinsic lysis concept. Ann N Y Acad Sci 1992;667:224-232.
39. 39. Yamamoto S, Mizoguchi T, Tamaki T, Ohkuchi M, Kimura S, Aoki N. Urinary thrombomodulin, its isolation and characterization. J Biochem 1993;113:433-440.